Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tamoxifen + tipifarnib
- Development stage
- Discontinued
- Lead developer
- Kura Oncology
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy consisting of tamoxifen, a selective estrogen receptor modulator (SERM), and tipifarnib, a farnesyltransferase inhibitor (FTI). This combination has been studied for the treatment of tamoxifen-resistant metastatic breast cancer. Preclinical data showed synergistic antiproliferative effects, with the combination producing greater G1 cell cycle arrest than either drug alone, marked inhibition of cyclin D1, and induction of the cell cycle inhibitor p27(kip1).
- Brand names
- Zarnestra + tamoxifenNolvadex + tipifarnib
02
Targets
ER (Estrogen receptor)FTase (Protein Farnesyltransferase)
Beyond the preview
Go deeper on tamoxifen + tipifarnib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tamoxifen + tipifarnib.